JESDUVROQ (daprodustat)
ERYTHROPOIESIS-STIMULATING AGENTS · ANEMIA IN HEMODIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE
GSK
Drug class
Hematopoietic-Hypoxia Inducible Factor Prolyl Hydroxyl Inhib
The phrase "Hematopoietic-Hypoxia Inducible Factor Prolyl Hydroxyl Inhib" represents an abbreviated compendial classification string for hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), which are oral hematopoietic agents. Read more about Hematopoietic-Hypoxia Inducible Factor Prolyl Hydroxyl Inhib
2 drugs in this class 2 manufacturers
Drugs in Hematopoietic-Hypoxia Inducible Factor Prolyl Hydroxyl Inhib
VAFSEO (vadadustat)
ERYTHROPOIESIS-STIMULATING AGENTS · ANEMIA IN HEMODIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE
AKEBIA THERAPEU
Filter & compare in the drug finder →
Opens the drug finder with Hematopoietic-Hypoxia Inducible Factor Prolyl Hydroxyl Inhib preselected. Add indication or manufacturer filters there.
The phrase "Hematopoietic-Hypoxia Inducible Factor Prolyl Hydroxyl Inhib" represents an abbreviated compendial classification string for hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), which are oral hematopoietic agents.
These drugs reversibly inhibit prolyl hydroxylase domain enzymes to prevent the degradation of hypoxia-inducible factor-alpha, thereby mimicking the cellular response to hypoxia and stimulating endogenous erythropoietin production alongside enhanced iron absorption and mobilization.
In clinical practice and regulatory evaluations, this therapeutic class is primarily indicated for treating anemia associated with chronic kidney disease, particularly in adults undergoing maintenance dialysis.
-
kidneynews.org
The phrase "Hematopoietic-Hypoxia Inducible Factor Prolyl Hydroxyl Inhib" represents an abbreviated compendial classification string for hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), which are oral hematopoietic agents In clinical practice and regulatory evaluations, this therapeutic class is primarily indicated for treating anemia associated with chronic kidney disease, particularly in adults undergoing maintenance dialysis
-
ashpublications.org
The phrase "Hematopoietic-Hypoxia Inducible Factor Prolyl Hydroxyl Inhib" represents an abbreviated compendial classification string for hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), which are oral hematopoietic agents These drugs reversibly inhibit prolyl hydroxylase domain enzymes to prevent the degradation of hypoxia-inducible factor-alpha, thereby mimicking the cellular response to hypoxia and stimulating endogenous erythropoietin production alongside enhanced iron absor...
-
pharmacytimes.com
These drugs reversibly inhibit prolyl hydroxylase domain enzymes to prevent the degradation of hypoxia-inducible factor-alpha, thereby mimicking the cellular response to hypoxia and stimulating endogenous erythropoietin production alongside enhanced iron absorption and mobilization
-
wikipedia.org
These drugs reversibly inhibit prolyl hydroxylase domain enzymes to prevent the degradation of hypoxia-inducible factor-alpha, thereby mimicking the cellular response to hypoxia and stimulating endogenous erythropoietin production alongside enhanced iron absorption and mobilization
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.